Abstracts tagged "rheumatoid arthritis (RA) and tocilizumab"

Abstract Number: 1440 • 2013 ACR/ARHP Annual Meeting
Effects Of Tocilizumab On Serum Cytokines In Rheumatoid Arthritis With An Inadequate Response To Disease-Modifying Antirheumatic Drugs
Sang Jin Lee^1,2, Kyung Rok Kim³, Sang Hyun Joo³, Jae Myung Lee³, In Ah Choi³, Joo Youn Lee², Hyun Jung Yoo², Eun Young Lee⁴, Eun Bong Lee¹, Won Park⁵, Sung Hwan Park⁶, Seung-Cheol Shim⁷, Dae-Hyun Yoo⁸, Han Joo Baek⁹, Hyun Ah Kim¹⁰, Soo Kon Lee¹¹, Yun Jong Lee¹, Young Eun Park¹², Hoon-Suk Cha¹³ and Yeong Wook Song^2,3, ¹Division of Rheumatology, Department of Internal Medicine, Rheumatology, Seoul National University, Seoul, South Korea, ²Department of molecular medicine and biophamaceutical sciences,Seoul National University, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, ⁴Internal medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ⁶Division of Rheumatology, Department of Internal Medicine, Rheumatology, The Catholic University, Seoul, South Korea, ⁷Medicine, Rheumatology, Eulji University, Daejeon, South Korea, ⁸Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁹Rheumatology, Rheumatology, Gachon University, Incheon, South Korea, ¹⁰Division of Rheumatology, Department of Internal Medicine, Hallym university, Kyunggi, South Korea, ¹¹Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, ¹²Rheumatology, Rheumatology, Pusan Nationl University, Pusan, South Korea, ¹³Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose: The objective of this study was to investigate the effects of tocilizumab on serum cytokines in rheumatoid arthritis (RA) patients with an inadequate response…
Abstract Number: 1344 • 2013 ACR/ARHP Annual Meeting
Optimal Rheumatoid Arthritis Patient Selection For Biological Treatment From Pharmacoeconomic Perspectives Based On The Institute Of Rheumatology, Rheumatoid Arthritis (IORRA) Cohort
Eiichi Tanaka¹, Eisuke Inoue², Yoko Shimizu³, Akiko Kobayashi², Naoki Sugimoto², Daisuke Hoshi², Kumi Shidara², Eri Sato³, Yohei Seto², Ayako Nakajima⁴, Shigeki Momohara², Atsuo Taniguchi² and Hisashi Yamanaka³, ¹Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁴Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: With the recent introduction of biological DMARDs, the economic burden of rheumatoid arthritis (RA) treatment has increased. Previous studies evaluated the cost-effectiveness of biologics,…
Abstract Number: 461 • 2012 ACR/ARHP Annual Meeting
Patterns of Tocilizumab Use, and Dosing Among Patients with Rheumatoid Arthritis in the Clinical Practice. Preliminary Analyses of ACT-Life Study
J.V. Tovar Beltrán¹, M.A. Guzmán Úbeda², I. Mateo Bernardo³, Rosario García-Vicuña⁴, M. Rodríguez-Gómez⁵, M. Belmonte-Serrano⁶, C. Marras⁷, E. Loza Cortina⁸, E. Pérez Pampin⁹, V. Vila Fayos¹⁰, A.B. Romero Silva¹¹ and A. Balsa¹², ¹Hospital General Universitario de Elche, Alicante, Spain, ²Hospital Universitario Virgen de las Nieves, Granada, Spain, ³Hospital Universitario 12 de Octubre, Madrid, Spain, ⁴Hospital Universitario La Princesa, Madrid, Spain, ⁵Complejo Hospitalario Universitario de Ourense, Ourense, Spain, ⁶Hospital General de Castellón, Castellón, Spain, ⁷Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, ⁸Hospital de Navarra, Navarra, Spain, ⁹Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, ¹⁰Hospital Comarcal de Vinaroz, Castellón, Spain, ¹¹Roche Farma, Madrid, Spain, ¹²Rheumatology, Hospital La Paz, Madrid, Spain
Background/Purpose: Currently, the available evidence about tocilizumab (TCZ) use for the treatment of rheumatoid arthritis (RA) in daily clinical practice is scarce. This study was…
Abstract Number: 2548 • 2012 ACR/ARHP Annual Meeting
Global Molecular Effects of Tocilizumab Therapy in Synovial Biopsies of Early Rheumatoid Arthritis Patients
Julie Ducreux¹, Adrien Nzeusseu Toukap², Frédéric A. Houssiau¹, Patrick Durez³ and Bernard Lauwerys³, ¹Institut de Recherche Expérimentale et Clinique, Pôle de Maladies Rhumatismales, Université catholique de Louvain, Brussels, Belgium, ²Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ³Department of Rheumatology, Université catholique de Louvain, Brussels, Belgium
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, systemic autoimmune inflammatory disease that is characterized by the presence of inflammatory cytokines, including interleukin-6 (IL-6). Here, we…
Abstract Number: 431 • 2012 ACR/ARHP Annual Meeting
Basic and Clinical Significance of Interleukin 6 (IL-6) in AA Amyloidosis with RA
Kazuyuki Yoshizaki, Prabha Tiwari, Lokesh P. Tripathi, Shandar Ahmad, Kenji Mizuguchi, Teppei Nishikawa-Matsumura, Tomoyasu Isobe and Soken-Nakazawa J. Song, Osaka University, Osaka, Japan
Background/Purpose: Cytokine-induced hepatic serum amyloid A (SAA) is associated with the pathogenesis of AA amylodosis, a fatal disease with deposition of AA amyloid fibril on…
Abstract Number: 2550 • 2012 ACR/ARHP Annual Meeting
Clinical, Radiographic, and Immunogenic Effects After 1 Year of Tocilizumab-Based Treatment Strategy with and without Methotrexate in Rheumatoid Arthritis: The ACT-RAY Study
Maxime Dougados¹, Karsten Kissel², Philip G. Conaghan³, Emilio Martin-Mola⁴, Georg A. Schett⁵, Howard Amital⁶, Ricardo M. Xavier⁷, OM Troum⁸, Corrado Bernasconi⁹ and T.W.J. Huizinga¹⁰, ¹Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ²F. Hoffmann-La Roche Ltd, Basel, Switzerland, ³University of Leeds, Leeds, United Kingdom, ⁴Rheumatology, Hospital Universitario La Paz, Madrid, Spain, ⁵Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁶Sheba Medical Center, Tel-Hashomer, Israel, ⁷Rheumatology Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, ⁸Medicine, USC Keck School of Medicine, Santa Monica, CA, ⁹Consultant, Basel, Switzerland, ¹⁰Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: 24-week data from ACT-RAY comparing an add-on strategy (tocilizumab [TCZ] + methotrexate [MTX]) with a switch strategy (TCZ + placebo [PBO]) in MTX-IR patients…
Abstract Number: 444 • 2012 ACR/ARHP Annual Meeting
Tocilizumab Improves Bone Mineral Density Compared with Abatacept in Patients with TNF Blockers-Resistant Active Rheumatoid Arthritis. an Open Label Randomized Controlled Trial
Kensuke Kume¹, Kanzo Amano¹, Susumu Yamada¹, Kazuhiko Hatta², Kuniki Amano³, Noriko Kuwaba⁴ and Hiroyuki Ohta⁵, ¹Rheumatology, Hiroshima Clinic, Hiroshima, Japan, ²Rheumatology, Hatta Clinic, Kure, Japan, ³Rheumatology, Sky Clinic, Hiroshima, Japan, ⁴Medical Research, Sanki Clinical Link, Hiroshima, Japan, ⁵Medical Research, hiroshima clinic, Hiroshima, Japan
Background/Purpose: To compare the effect of tocilizumab(TCZ) plus methotrexate (MTX), with the effect of abatacept(ABT) plus MTX on bone mineral density(BMD) in TNF blockers resistant…
Abstract Number: 2505 • 2012 ACR/ARHP Annual Meeting
Involvment of CD4⁺ FoxP3⁺ Regulatory T Cells in Interleukin-6 Receptor Targeted Treatment in Murine Arthritis and Rheumatoid Arthritis
Allan Thiolat¹, Jerome Biton¹, Luca Semerano¹, Yves-Marie Pers², Pierre Portales², Delphine Lemeiter¹, Patrice Decker¹, Christian Jorgensen², Pascale Louis-Plence², Natacha Bessis³ and Marie-Christophe Boissier⁴, ¹EA4222, Li2P, University Paris 13, Sorbonne Paris Cité and Rheumatology Department, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, 93009, France, Bobigny, France, ²Department of therapy & Immuno-Rhumatology, Inserm U844, CHU saint-Eloi, Université Montpellier 1, CHU Lapeyronie, Montpellier, France, ³INSERM UMR 1125, Li2P, University Paris 13, Sorbonne Paris Cité and Rheumatology Department, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, France, ⁴INSERM UMR 1125, Li2P, University Paris 13, Sorbonne Paris Cité, Bobigny, France
Background/Purpose: Studies have demonstrated the clinical efficacy of tocilizumab, a humanized anti-IL-6 receptor (R) antibody (Ab), in patients with rheumatoid arthritis (RA). The rational for…
Abstract Number: L8 • 2012 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Parallel-Group Study of the Safety and Efficacy of Tocilizumab Subcutaneous Versus Placebo in Combination with Traditional Dmards in Patients with Moderate to Severe Rheumatoid Arthritis (BREVACTA)
Alan J. Kivitz¹, Ewa Olech², Michael A. Borofsky³, Beatriz M. Zazueta⁴, Federico Navarro-Sarabia⁵, Lucy Rowell⁶, Clare Nasmyth-Miller⁶ and Janet E. Pope⁷, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Internal Medicine, University of Nevada School of Medicine, Las Vegas, NV, ³Clinical Research Center of Reading, Reading, PA, ⁴Reumatologia, Centro de Investigacion en Enfermedades Reumaticas, Mexicali, Mexico, ⁵Rheumatology, University Hospital Virgen Macarena, Sevilla, Spain, ⁶Roche, Welwyn Garden City, United Kingdom, ⁷Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada
Background/Purpose: The intravenous formulation of tocilizumab (TCZ) has demonstrated efficacy with a manageable safety profile in patients (pts) with rheumatoid arthritis (RA) in multiple clinical…
Abstract Number: 2166 • 2012 ACR/ARHP Annual Meeting
Identification of Serological Biomarker Profiles Associated with Response to IL-6 Intervention in Rheumatoid Arthritis
Morten Asser Karsdal¹, Anne C. Bay-Jensen², Inger Byrjalsen³, Andrew Kenwright⁴, Adam Platt⁴, Thierry Sornasse⁵ and Claus Christiansen⁶, ¹Nordic Bioscience A/S, Herlev, Denmark, ²Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ³Research & Development, Nordic Bioscience, Herlev, Denmark, ⁴Roche, Welwyn Garden City, United Kingdom, ⁵Product Development Immunology, Genentech, Inc., South San Francisco, USA, San Fransisco, CA, ⁶CCBR, Ballerup, Denmark
Background/Purpose: RA is characterized by poly-articular synovial inflammation, cartilage loss and erosion of subchondral bone. It is critical to diagnose and effectively treat the disease…
Abstract Number: 2167 • 2012 ACR/ARHP Annual Meeting
Serum Based Biomarkers of Joint Destruction Can Identify Responders and Non-Responder to Tocilizumab
Anne C. Bay-Jensen¹, Inger Byrjalsen², Claus Christiansen³ and Morten Asser Karsdal⁴, ¹Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ²Research & Development, Nordic Bioscience, Herlev, Denmark, ³CCBR, Ballerup, Denmark, ⁴Nordic Bioscience A/S, Herlev, Denmark
Background/Purpose: RA is characterized by synovial inflammation, cartilage loss and erosion of subchondral bone. It is critical to diagnose and effectively treat the disease early…
Abstract Number: 2156 • 2012 ACR/ARHP Annual Meeting
Anti-Cyclic Citrullinated Protein Antibodies As a Predictor of Response to Tocilizumab in Patients with Rheumatoid arthritis A Prospective Study
Kensuke Kume¹, Kanzo Amano¹, Susumu Yamada¹, Kuniki Amano², Kazuhiko Hatta³, Hiroyuki Ohta⁴ and Noriko Kuwaba⁵, ¹Rheumatology, Hiroshima Clinic, Hiroshima, Japan, ²Rheumatology, Sky Clinic, Hiroshima, Japan, ³Rheumatology, Hatta Clinic, Kure, Japan, ⁴Medical Research, hiroshima clinic, Hiroshima, Japan, ⁵Medical Research, Sanki Clinical Link, Hiroshima, Japan
Background/Purpose: Tocilizumab, interleukin-6 receptor antibody is very effective in patients with rheumatoid arthritis (RA). Anti-cyclic citrullinated protein antibodies (ACPA) are highly specific and sensitive for…
Abstract Number: 2121 • 2012 ACR/ARHP Annual Meeting
A Multi-Biomarker Disease Activity (VECTRA™ DA Algorithm) Score Reflects Clinical Disease Activity and Structural Changes in Rheumatoid Arthritis Patients Treated with Tocilizumab
Yoshiya Tanaka¹, Kentaro Hanami², Hisashi Tasaka¹, Shunsuke Fukuyo¹, Douglas J. Haney³, Nadine Defranoux³, Rebecca Bolce³, Guy Cavet³, David Chernoff³, Kunihiro Yamaoka¹, Kazuyoshi Saito¹ and Shintaro Hirata¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²The First Department of Internal Medicinei, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³Crescendo Bioscience Inc., South San Francisco, CA
Background/Purpose: The multi-biomarker disease activity (MBDA) score assessed with 0.2 mL serum has been reported as a novel composite disease activity index for patients with…
Abstract Number: 1762 • 2012 ACR/ARHP Annual Meeting
IL-6 Receptor Inhibition by Tocilizumab Modulates Double Negative (CD19+IgD-CD27-) B Cells in RA
Zafar Mahmood¹, Khalid Muhammad¹, Petra Roll², Stefan Kleinert³, Thomas Dörner⁴ and Hans Peter Tony⁵, ¹Department of Medicine II, Rheumatology/Clinical Immunology, University of Würzburg, Würzburg, Germany, ²Department of Medicine II, Rheumatology/Clinical immunology, University of Würzburg, Würzburg, Germany, ³Rheumatology/Clinical Immunology,, University Hospital Würzburg, Würzburg, Germany, ⁴CC12, Dept. Medicine/Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany, ⁵Rheumatology/Immunology, University of Würzburg, Würzburg, Germany
Background/Purpose: Double negative (CD19+IgD-CD27-) B cells have been reported to be part of human memory B cell compartment. Detailed studies of DN B cells in…
Abstract Number: 1336 • 2012 ACR/ARHP Annual Meeting
Changes in the Levels of Anti-Cyclic Citrullinated Protein Antibody and Immunoglobulins in Rheumatoid Arthritis Patients After Administration of Tocilizumab
Masao Sato¹, Masao Takemura², Ryuki Shinohe³, Tsuneo Watanabe² and Katsuji Shimizu³, ¹Rheumatology, Matsunami General Hospital, Gifu, Japan, ²Informative Clinical Medicine, Gifu University, Gifu, Japan, ³Orthopaedic Surgery, Gifu University, Gifu, Japan
Background/Purpose: The recently established scoring system of American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) early arthritis diagnosis criteria have assigned scores of 0, 1,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.